FDA 483 - Groupe Parima Inc. - April 27, 2018

An FDA inspection of Groupe Parima Inc. in Montreal revealed significant deficiencies in data integrity, equipment maintenance, and facility upkeep. The firm failed to ensure electronic data backup integrity, perform routine equipment checks, and maintain its manufacturing buildings in a good state of repair. These observations indicate a lack of adherence to good manufacturing practices for drug products.